477291-09-1

Usage

InChI:InChI=1/C12H7ClF3NOS/c1-6-9(10(13)18)19-11(17-6)7-2-4-8(5-3-7)12(14,15)16/h2-5H,1H3

Upstream product

• 144059-86-9 4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carboxylic acid 
• 72505-21-6 4-trifluoromethylbenzthioamide 
• 175277-03-9 4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole-5-carboxylic acid ethyl ester 

Downstream Products

• 1083418-45-4 4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 800373-88-0 C₂₇H₂₇F₃N₂O₄S 
• 343321-97-1 N-methyl-2-methyl-2-[4-{[(4-methyl-2-[4-trifluoromethylphenyl]-1,3-thiazol-5-ylcarbonyl)amino]methyl}phenoxy]propionic acid ethyl ester 
• 343321-95-9 2-methyl-2-[4-{[(4-methyl-2-[4-trifluoromethylphenyl]-1,3-thiazol-5-ylcarbonyl)amino]methyl}phenoxy]propionic acid ethyl ester 

Relevant academic research and scientific papers

Thiazole-5-carboxamide compounds, and its preparation, and pharmaceutical composition and use thereof (by machine translation)

The invention relates to a novel 2-phenylthiazole-5-methanamide compound shown as a general formula I, a precursor, a stereo isomer and physiologically-acceptable salt thereof, a medicinal composition containing the compound, and an application of the compound as the aspect of medicine.

Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARα agonists. 1. Discovery of a novel series of potent HDLc raising agents

The peroxisome proliferator activated receptors PPARα, PPARγ, and PPARδ are ligand-activated transcription factors that play a key role in lipid homeostasis. The fibrates raise circulating levels of high-density lipoprotein cholesterol and lower levels of triglycerides in part through their activity as PPARα agonists; however, the low potency and restricted selectivity of the fibrates may limit their efficacy, and it would be desirable to develop more potent and selective PPARα agonists. Modification of the selective PPARδ agonist 1 (GW501516) so as to incorporate the 2-aryl-2-methylpropionic acid group of the fibrates led to a marked shift in potency and selectivity toward PPARα agonism. Optimization of the series gave 25a, which shows EC50 = 4 nM on PPARα and at least 500-fold selectivity versus PPARγ and PPARγ. Compound 25a (GW590735) has been progressed to clinical trials for the treatment of diseases of lipid imbalance.

TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-α ACTIVATORS

PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-c